Every autumn, clinicians see the same pattern walk through the door: patients who catch every circulating virus, who take three weeks to clear what used to resolve in five days, who describe themselves as “run down” long before the first frost. The reflexive explanation is exposure — new classrooms, indoor gatherings, recycled office air. But exposure alone does not explain why some patients weather a season of pathogens with barely a sniffle while others cycle through one respiratory infection after another. A more complete explanation lives at the intersection of two regulatory systems that rarely make it into the differential: the endocannabinoid system (ECS) and the hypothalamic-pituitary-adrenal (HPA) axis.
Clinical Endocannabinoid Deficiency as a Framework
Neurologist and cannabinoid researcher Ethan Russo first proposed that a subset of treatment-resistant conditions, including migraine, fibromyalgia, and irritable bowel syndrome, share a common underlying defect: insufficient endocannabinoid tone. Russo’s hypothesis rests on the premise that everyone carries a baseline level of anandamide and 2-arachidonoylglycerol activity, along with receptor density and sensitivity, and that when this tone falls below a functional threshold, the nervous system loses one of its principal buffering mechanisms against pain, mood dysregulation, and gut dysfunction. A decade of subsequent research supports the broader premise that ECS tone is not fixed; it is shaped by diet, the gut microbiome, chronic stress, and inflammatory load, and it can be depleted.[1]
What Russo’s original framework did not emphasize as heavily, but what the cannabinoid-immunology literature has clarified since, is that the same endocannabinoid tone he described for pain and mood syndromes also governs immune competence.
CB2 Receptors as an Immune Thermostat
The CB2 receptor is expressed predominantly on immune cells, including macrophages, dendritic cells, natural killer cells, and B and T lymphocytes, making it functionally the peripheral arm of the ECS.[2]Activation of CB2 by endogenous anandamide expands regulatory CX3CR1-high macrophages in the gut and promotes differentiation of Tr1 regulatory T cells, effectively teaching the immune system when to stand down.[3] This is not a minor academic point. A common CB2 gene polymorphism, the Q63R variant, that blunts endocannabinoid-mediated immune inhibition is overrepresented in patients with autoimmune disease, and carriers show a measurably reduced anti-inflammatory response to endogenous cannabinoids in vitro.[4] When CB2 signaling is weak, whether from genetic variation, receptor downregulation, or a shortage of endogenous ligand, the immune system loses one of its principal off-switches, and the same defect that predisposes toward autoimmune overreaction also predisposes toward inefficient pathogen clearance.
Nowhere is this more concretely demonstrated than in respiratory syncytial virus (RSV) research. In a cohort of Iranian infants with acute respiratory tract infection, the CB2 Q63R variant tracked with more than a doubling of the risk of severe illness following RSV infection, and children homozygous for the low-function allele were more than three times as likely to require hospitalization. The same research group went on to show, in a mouse model, that pharmacologic blockade of CB2 during RSV infection increased airway immune cell influx, amplified cytokine and chemokine production, and worsened lung pathology, while CB2 activation reversed each of these findings.[5] A follow-up study demonstrated an analogous role for CB1: blocking CB1 receptors during RSV infection intensified the inflammatory cascade, while pharmacologic activation calmed it.[6] Together these findings establish, in a real respiratory pathogen model, that endocannabinoid signaling is not incidental to immune competence; it is one of the mechanisms that determines whether a respiratory infection stays mild or turns severe.
The cannabinoid-immunology literature has clarified that the same endocannabinoid tone involved in pain and mood syndromes also governs immune competence.
When the Adrenal System Joins the Problem
Endocannabinoid tone does not operate in isolation from the stress axis. Chronic activation of the HPA axis, the pattern clinicians casually label adrenal fatigue, produces impaired negative feedback and glucocorticoid receptor resistance over time. Rather than the sustained immune suppression classically attributed to cortisol, prolonged HPA dysregulation paradoxically shifts the system toward a pro-inflammatory, cytokine-imbalanced state, a pattern now linked mechanistically to autoimmune conditions including lupus, rheumatoid arthritis, and multiple sclerosis.[7] The endocannabinoid system sits directly inside this feedback loop: endocannabinoid signaling is understood to participate in resetting HPA axis activity following a stressor, with CB1 receptor engagement implicated in normalizing corticosterone secretion.[8] When chronic stress erodes endocannabinoid tone at the same time it dysregulates cortisol output, a patient loses two interdependent regulatory systems that would otherwise correct each other. The result is an immune system that oscillates between insufficient surveillance against pathogens and excessive, poorly targeted inflammatory reactivity, which is precisely the clinical picture of the patient who is simultaneously catching everything and inflamed.
CBD and Beta-Caryophyllene: Restoring Tone Rather Than Suppressing Symptoms
This is the therapeutic logic behind pairing cannabidiol (CBD) with beta-caryophyllene (BCP) rather than relying on either alone. CBD is not a direct CB1/CB2 agonist; it has instead been shown to bind fatty acid binding proteins, the intracellular carriers that shuttle anandamide to its degrading enzyme, competitively slowing anandamide breakdown and raising the amount available for receptor signaling, a mechanism proposed to underlie some of CBD’s clinical effects.[9] BCP, by contrast, is a dietary sesquiterpene found in copaiba, black pepper, and hemp that functions as a full, selective CB2 agonist, the only common terpene shown to directly engage a cannabinoid receptor.[10] Across models ranging from mycobacterial pleurisy to collagen-antibody-induced arthritis to periodontal inflammation, BCP suppresses neutrophil chemotaxis and pro-inflammatory cytokines such as TNF-alpha, IL-1beta, and IL-6, while raising anti-inflammatory IL-10, largely through CB2 and cross-talk with PPAR-gamma.[11] [12] Given the CB2 pathway’s demonstrated role in RSV outcomes, that same mechanism is directly relevant to seasonal respiratory vulnerability.
Supporting the Endocannabinoid System and Immune System
In clinical practice I utilize a CBD blend that offers 25 mg of CBD and 10 mg of beta-caryophyllene, along with limonene, per two-capsule serving, using VESIorb lipid-based delivery to improve absorption of these hydrophobic constituents. This addresses the endocannabinoid side of the equation described above.
I pair the above formula with a conventional immune-nutrient base of vitamin C, zinc picolinate, astragalus root, EpiCor fermentate, olive leaf extract, berberine, N-acetyl-cysteine, garlic, and citrus bioflavonoids, targeting innate immune readiness, mucosal defense, and antioxidant capacity through separate, well-characterized mechanisms. Neither arm substitutes for the other; the underlying premise is that immune competence during high-exposure, high-stress seasons depends on both adequate ECS tone and adequate raw material for the innate immune response.
Positioned this way, the clinical goal is to lessen susceptibility and provide nutritional support is intended less as a stand-alone cold-and-flu product and more as one component of a foundational wellness protocol, one that should also include attention to sleep architecture, adaptogenic HPA support, and gut barrier integrity, particularly heading into autumn and the school year, when close-quarters exposure and disrupted routines place simultaneous strain on both the ECS and the adrenal system. For patients presenting with the recurrent-infection-plus-fatigue pattern so common this time of year, assessing both endocannabinoid tone and HPA function, rather than in isolation, is where the clinical picture most readily resolves based on my 34 years of clinical experience.
References
[1]Russo, E.B. (2016) ‘Clinical Endocannabinoid Deficiency Reconsidered: Current Research Supports the Theory in Migraine, Fibromyalgia, Irritable Bowel, and Other Treatment-Resistant Syndromes’, Cannabis and Cannabinoid Research, 1(1), pp.154–165.
[2]Turcotte, C., Blanchet, M.-R., Laviolette, M. and Flamand, N. (2016) ‘The CB2 receptor and its role as a regulator of inflammation’, Cellular and Molecular Life Sciences, 73(23), pp.4449–4470.
[3]Acharya, N., Penukonda, S., Shcheglova, T., Hagymasi, A.T., Basu, S. and Srivastava, P.K. (2017) ‘Endocannabinoid system acts as a regulator of immune homeostasis in the gut’, Proceedings of the National Academy of Sciences, 114(19), pp.5005–5010.
[4]Sipe, J.C., Arbour, N., Gerber, A. and Beutler, E. (2005) ‘Reduced endocannabinoid immune modulation by a common cannabinoid 2 (CB2) receptor gene polymorphism: possible risk for autoimmune disorders’, Journal of Leukocyte Biology, 78(1), pp.231–238.
[5]Tahamtan, A., Samieipoor, Y., Nayeri, F.S., Rahbarimanesh, A.A., Izadi, A., Rashidi-Nezhad, A., Tavakoli-Yaraki, M., Farahmand, M., Bont, L., Shokri, F., Mokhatri-Azad, T. and Salimi, V. (2018) ‘Effects of cannabinoid receptor type 2 in respiratory syncytial virus infection in human subjects and mice’, Virulence, 9(1), pp.217–230.
[6]Tahamtan, A., Tavakoli-Yaraki, M., Shadab, A., Rezaei, F., Marashi, S.M., Shokri, F., Mokhatri-Azad, T. and Salimi, V. (2018) ‘The role of cannabinoid receptor 1 in the immunopathology of respiratory syncytial virus’, Viral Immunology, 31(4), pp.292–298.
[7]Nunez, S.G., Rabelo, S.P., Subotic, N., Caruso, J.W. and Knezevic, N.N. (2025) ‘Chronic stress and autoimmunity: the role of HPA axis and cortisol dysregulation’, International Journal of Molecular Sciences, 26(20), article 9994.
[8]Hassanzadeh, P. and Hassanzadeh, A. (2011) ‘The role of the endocannabinoids in suppression of the hypothalamic-pituitary-adrenal axis activity by doxepin’, Iranian Journal of Basic Medical Sciences, 14(5), pp.414–421.
[9]Deutsch, D.G. (2016) ‘A personal retrospective: elevating anandamide (AEA) by targeting fatty acid amide hydrolase (FAAH) and the fatty acid binding proteins (FABPs)’, Frontiers in Pharmacology, 7, article 370.
[10]Sharma, C., Al Kaabi, J.M., Nurulain, S.M., Goyal, S.N., Kamal, M.A. and Ojha, S. (2021) ‘Beta-caryophyllene, a natural dietary CB2 receptor selective cannabinoid, can be a candidate to target the trinity of infection, immunity, and inflammation in COVID-19’, Frontiers in Pharmacology, 12, article 590201.
[11]Irrera, N., D’Ascola, A., Pallio, G., Bitto, A., Mazzon, E., Mannino, F., Squadrito, V., Arcoraci, V., Minutoli, L., Campo, G.M., Avenoso, A., Bongiorno, E.B., Vaccaro, M., Squadrito, F. and Altavilla, D. (2019) ‘Beta-caryophyllene mitigates collagen antibody induced arthritis (CAIA) in mice through a cross-talk between CB2 and PPAR-γ receptors’, Biomolecules, 9(8), article 326.
[12]Andrade-Silva, M., Correa, L.B., Candéa, A.L.P., Cavalher-Machado, S.C., Barbosa, H.S., Rosas, E.C. and Henriques, M.G. (2016) ‘The cannabinoid 2 receptor agonist β-caryophyllene modulates the inflammatory reaction induced by Mycobacterium bovis BCG by inhibiting neutrophil migration’, Inflammation Research, 65(11), pp.869–879.
